PHARMACISTS: Come October, Rates For Generics May Get Scary

Why This Topic Matters

The rule has potential financial implications for pharmacies that serve Medicaid beneficiaries and may influence payment practices beyond Medicaid. Readers who manage pharmacy revenue, reimbursement compliance, or payer policy need to understand the scope, timing, and areas of ongoing comment.

Article Sections

1. Beware final rule for Medicaid payments

   Introduces the CMS rule and frames its relevance to pharmacy revenue and Medicaid reimbursement. Sets up the policy change and the groups most likely to follow it closely.

2. Background

   Explains the legislative and regulatory context for the rule and the general framework for federal upper limits and average manufacturer price. Describes how the rule fits into existing Medicaid drug payment policy.

3. Hit hard

   Summarizes expected operational and financial effects for different pharmacy sectors. Also notes the potential impact on access for Medicaid beneficiaries and possible spillover to other payers.

4. Devil Is In The Details

   Discusses stakeholder concerns about the pricing methodology and the inclusion of certain market discounts in the calculation process. Includes the general dispute between pharmacy groups, GAO, and CMS over the policy's effect on reimbursement.

5. Ray of hope

   Covers CMS statements about possible relief through other pharmacy fees and state-level actions. Describes the administrative process for adjusting dispensing-related payments.

6. What To Do: Comment Now For Fairer Payments

   Outlines the public comment areas identified by CMS and the rule’s implementation timing. Summarizes the types of issues still open for later agency response.

7. Timeline

   Provides the effective-date information for the rule and notes when additional CMS action is expected. Highlights the rule's schedule for comments and future publication.